Table 1 Demographic data.
Full cohort 500 eyes /399 patients | Optimal 171 eyes/153 patients | Suboptimal 329 eyes/285 patients | |
|---|---|---|---|
Age (years) at first anti-VEGF treatment (patients) | |||
Mean ± SD | 61.5 ± 13.5 | 59.3 ± 13.6 | 62.6 ± 13.2 |
Range | 21.7–94.7 | 25.1–94.7 | 21.7–90.3 |
Male gender, no (%) | 261 (65.4%) | 94 (61.4%) | 194 (68.1%) |
BRVA at baseline (mean ETDRS) | 64.3 letters | 56.2 letters | 68.5 letters |
Diabetes type 1/2/unknown | |||
No | 53/319/27 | 22/119/12 | 41/229/15 |
% | 13.3/79.9/6.8% | 14.4/77.8/7.8% | 14.4/80.4/5.3% |
Duration of diabetes at first anti-VEGF treatment (first eye), years | |||
All | 15.24 ± 11.01 | 15.24 ± 10.61 | 15.47 ± 11.55 |
Type 1 | 20.83 ± 8.84 | 18.95 ± 9.67 | 21.18 ± 7.66 |
Type 2 | 14.14 ± 11.12 | 14.38 ± 10.72 | 14.32 ± 11.92 |
Ethnicity, no (%) | |||
White British/other | 306 (76.7%) | 103 (67.3%) | 229 (80.4%) |
Asian (Bangladeshi, Indian, Pakistani) | 43 (10.8%) | 19 (12.4%) | 27 (9.5%) |
Other Asian | 5 (1.3%) | 3 (2%) | 4 (1.4%) |
Chinese | 1 (0.3%) | 1 (0.7%) | 0 (0%) |
Black | 8 (2%) | 5 (3.3%) | 4 (1.5%) |
Mixed | 3 (0.8%) | 2 (1.3%) | 2 (0.7%) |
Other | 6 (1.5%) | 4 (2.6%) | 4 (1.4%) |
Not stated | 27 (6.8%) | 16 (10.5%) | 15 (5.3%) |
Baseline medical conditions, no (%) | |||
Renal failure | 6/377 (1.6%) | 2/145 (1.4%) | 4/269 1.5% |
Hypertension | 101/377 (26.8%) | 32/145 (22.1%) | 71/269 (26.4%) |
Ophthalmic history (per eyes), no (%) | |||
Cataract | 359 (71.8%) | 119 (69.6%) | 240 (72.9%) |
Glaucoma | 10 (2%) | 5 (2.9%) | 5 (1.5%) |
Previous panretinal photocoagulation (PRP) | 92(18.4%) | 36 (21.1%) | 56 (17%) |
Previous mac laser | 160 (32%) | 47 (27.5%) | 113 (34.3%) |
Previous intravitreal injections (IVI) | 2 (0.4%) | 0 (0%) | 2 (0.6%) |
Previous vitrectomy | 7 (1.4%) | 2 (1.2%) | 5 (1.8%) |
